Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Aging and HIV an evolving understanding

Aging and HIV an evolving understanding EDITORIAL URRENT PINION a b Amy Justice and Julian Falutz The increasing availability of effective antiretroviral more than 95% of whom are on ART, have a median treatment (ART) has dramatically extended life CD4 cell count in 2011 below 500 cells. Thus, expectancy for those with HIV infection [1]. As a less than half of those aging with HIV have a normal result, people are aging with HIV [2], but data on this life expectancy (www.naaccord.org/dossier/NA- new phenomenon remain somewhat limited and ACCORD_Dossier 20140325.pdf). Further, whether opinions vary. Some experts contend, now that long-term HIV effects of microbial translocation, we are successful at suppressing HIV-1 RNA, that viral reservoirs, and chronic inflammation among HIV research and healthcare resources should be suppressed patients will alter these estimates with exclusively dedicated to ensuring access to ART time is not yet known [5,6]. and developing an effective vaccine. They argue Another common argument from HIV and against spending limited resources on complex aging ‘skeptics’ is that any increased risk we observe issues of aging with HIV because many of these for non-AIDS conditions among those with HIV issues have bedeviled aging researchers for decades. compared with demographically similar uninfected Some also suggest http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Aging and HIV an evolving understanding

Falutz, Julian
Current Opinion in HIV and Aids , Volume 9 (4) – Jul 1, 2014
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/aging-and-hiv-an-evolving-understanding-NdA5xI5WM4

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
1746-630X
eISSN
1746-6318

Abstract

EDITORIAL URRENT PINION a b Amy Justice and Julian Falutz The increasing availability of effective antiretroviral more than 95% of whom are on ART, have a median treatment (ART) has dramatically extended life CD4 cell count in 2011 below 500 cells. Thus, expectancy for those with HIV infection [1]. As a less than half of those aging with HIV have a normal result, people are aging with HIV [2], but data on this life expectancy (www.naaccord.org/dossier/NA- new phenomenon remain somewhat limited and ACCORD_Dossier 20140325.pdf). Further, whether opinions vary. Some experts contend, now that long-term HIV effects of microbial translocation, we are successful at suppressing HIV-1 RNA, that viral reservoirs, and chronic inflammation among HIV research and healthcare resources should be suppressed patients will alter these estimates with exclusively dedicated to ensuring access to ART time is not yet known [5,6]. and developing an effective vaccine. They argue Another common argument from HIV and against spending limited resources on complex aging ‘skeptics’ is that any increased risk we observe issues of aging with HIV because many of these for non-AIDS conditions among those with HIV issues have bedeviled aging researchers for decades. compared with demographically similar uninfected Some also suggest

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jul 1, 2014

There are no references for this article.